Skip to search formSkip to main contentSkip to account menu

peritoneal cavity cancer

Known as: cancer peritoneal, peritoneum cancer, Malignant neoplasm of peritoneum, unspecified 
A primary or metastatic malignant neoplasm involving the peritoneum. Representative examples include carcinoma and malignant mesothelioma.
National Institutes of Health

Related topics

Related topics

6 relations
Abdominal CavityNeoplastic Cellcancer cell

Narrower (1)

Malignant Mesothelioma of Peritoneum

Broader (2)

Peritoneal NeoplasmsPeritoneum

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Mechanisms of the Formation of Peritoneal Surface Malignancy on Omental Milky Spots from Low Grade Appendiceal Mucinous Carcinoma
Mechanisms of the Formation of Peritoneal Surface Malignancy on Omental Milky Spots from Low Grade Appendiceal Mucinous Carcinoma… 
2014
2014
Effects of Laparosopic Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Metastasis from Gastric Cancer
Background: The purpose of this manuscript is to report the direct effects of hyperthermic intraperitoneal chemotherapy (HIPEC… 
2010
2010
Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic/pharmacodynamic (PK/PD) modeling to facilitate phase III dose…
5042 Background: The exposure-response relationships of AMG 386 (an investigational peptide-Fc fusion protein that neutralizes… 
2010
2010
A phase II evaluation of nab-paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group (GOG) study.
5010 Background: Nab-paclitaxel (Abraxane, ABX) is a novel cremophor-free nanoparticle of albumin-stabilized paclitaxel, which… 
2008
2008
Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC)
5551 Background: Patients (pts) with platinum refractory OC have limited treatment options. Bevacizumab, an anti- angiogenesis… 
2008
2008
Phase II multicenter open‐label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study
The topoisomerase I agents are established as a therapy in recurrent ovarian cancer. Karenitecin, an analog of topotecan with… 
2008
2008
Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary…
5577 Background: Targeting angiogenesis pathways is becoming an important therapeutic option for patients with ovarian cancer. We… 
2008
2008
A phase II evaluation of pemetrexed (LY231514, IND #40061) in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: A study of the gynecologic oncology…
5524 Objective: To estimate the anti-tumor activity of pemetrexed (LY231514) in patients with persistent or recurrent platinum… 
1981
1981
Effect of complement activation on the biosynthesis of prostacyclin (PGI2) by rabbit peritoneum in vitro.
1932
1932
Ein Beitrag zur Toxikologie des Orthotrikresylphosphates
Zusammenfassungp-und m-Trikresylphosphat werden von Schleimhäuten, Peritoneum und äußerer Haut überhaupt nicht oder nur ganz…